Human Genome Sciences, Inc.
News and overview for Human Genome Sciences, Inc.
Human Genome Sciences and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Lymphoid Tumors [Press Release]
Business Wire | 1 day 21 hours 43 minutes ago
Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.
Human Genome, Vertex, Amylin in play - MarketWatch
MarketWatch | 22 days 17 hours 34 minutes ago
The Dow Jones Industrial Average /quotes/comstock/10w!i:dji/delayed (INDU 9,808, +95.30, +0.98%) advanced about 110 points to 9,822.
Human Genome, GSK see progress with lupus drug - MarketWatch
MarketWatch | 23 days 2 hours 55 minutes ago
Human Genome, GSK see progress with lupus drug
BioMarin, Human Genome lead drug stocks higher - MarketWatch
MarketWatch | 26 days 15 hours 53 minutes ago
Shares of BioMarin /quotes/comstock/15*!bmrn/quotes/nls/bmrn (BMRN 15.81, +0.13, +0.83%) jumped 4% to $16.24.
Human Genome Sciences faces FDA regulatory delay on anthrax treatment
Sun (Baltimore), The | 7 days 4 hours 8 minutes ago
Human Genome Sciences Inc. said Monday the Food and Drug Administration will not approve the company's anthrax treatment until it receives additional information on the potential drug.
FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA
News-Medical.Net | 8 days 20 hours 21 minutes ago
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Companys Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional information needed to complete the review of a BLA.
Human Genome Sciences Receives Complete Response Letter from FDA for Raxibacumab Biologics License Application [Press Release]
Business Wire | 8 days 21 hours 43 minutes ago
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional information needed to complete the review of a BLA.
Human Genome sees FDA delay with anthrax treatment
Forbes | 8 days 16 hours 55 minutes ago
ROCKVILLE, Md. -- Human Genome Sciences Inc. said Monday the Food and Drug Administration will not approve the company's anthrax treatment until it receives additional information on the potential drug.
Human Genome Sciences books smaller 3Q loss
Richmond Times-Dispatch (Va.) | 26 days 12 hours 8 minutes ago
ROCKVILLE, Md. (AP) -- Human Genome Sciences Inc. said Thursday it booked a smaller loss in the third quarter because research and development spending dropped sharply.
Human Genome Sciences reports smaller 3Q loss after completing tests of lupus drug Benlysta
Sun (Baltimore), The | 26 days 12 hours 5 minutes ago
Human Genome Sciences Inc. said Thursday it booked a smaller loss in the third quarter because research and development spending dropped sharply.
Human Genome Sciences And Glaxosmithkline Announce Positive Results In Second Of Two Phase 3 Trials Of Benlysta™ In Systemic Lupus Erythematosus
Bioresearch Online | 20 days 3 hours 18 minutes ago
Carlo Russo, M.D., Senior Vice President, Biopharm Development, GSK, said, "The results from this second pivotal Phase 3 trial reinforce our belief that belimumab could deliver a significant therapeutic option for patients with lupus who have had no new treatment in fifty years. We look forward to continuing our collaboration with HGS in order to bring this important medicine to patients."
Human Genome Sciences Announces Third Quarter 2009 Financial Results and Key Developments [Press Release]
Business Wire | 26 days 13 hours 38 minutes ago
Human Genome Sciences, Inc. (Nasdaq:HGSI) today announced financial results for the quarter ended September 30, 2009, and provided highlights of recent key developments.
Human Genome Sciences Announces $75 Million Milestone Payment for ZALBIN Progress [Press Release]
Business Wire | 36 days 22 hours 43 minutes ago
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis
News-Medical.Net | 36 days 21 hours 22 minutes ago
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBINâ?¢ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
Human Genome Sciences to Host November 2nd Conference Call to Discuss Top-Line Results from Second Phase 3 Trial of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus [Press Release]
Business Wire | 40 days 13 hours 38 minutes ago
Human Genome Sciences, Inc. (Nasdaq:HGSI) today announced that it expects to have top-line 52-week results available on Monday, November 2nd, from BLISS-76, the second of two pivotal Phase 3 clinical trials of BENLYSTA™ (belimumab) in systemic lupus erythematosus (SLE).
Sign up for ANA SmartBrief
Company Overview
| Company: | Human Genome Sciences, Inc. |
|---|---|
| Industry: | Biopharmaceuticals & Biotherapeutics |
| Website: | http://www.hgsi.com |
Human Genome Sciences (HGS) knows that the path to good health starts at the molecular level. Using its expertise in human genetics, the firm is working on therapies for infectious and autoimmune diseases and cancer. One of its lead candidates is Albuferon, a long-acting version of protein therapy interferon alpha, that it is developing with Novartis to treat hepatitis C. Monoclonal antibody LymphoStat-B is also in later stages of clinical testing; GlaxoSmithKline is HGS' partner on the drug. With funding from the US government, HGS is developing an antibody that fights anthrax infection, and it has several anticancer antibodies at earlier stages of development.
Key Numbers
| Sales in U.S. Dollars (mil.) | 48.4 (2008) |
|---|---|
| One-year % Growth in Sales | 15.7 (2008) |
| Net Income in U.S. Dollars (mil.) | -244.9 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 880 (2008) |
| One-year % Growth in Number of Employees | 3.5 (2008) |
| Fiscal Year-End | December |